Valencia, Spain, October 9, 2025 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, announced today its participation in the following investor and industry events:
5th Annual Needham Private Biotech and MedTech Company Virtual 1x1 Forum
o October 14-15, 2025 (virtual)
o Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference
Chardan/Sanofi: The Double Helix Den: A closed-door symposium enabling unfiltered conversations on genetic medicines
o October 20, 2025, New York, NY
o Mr. Legros will be participating in a panel discussion titled “Clinical stage development: Balancing safety and maximizing clinical benefit”
Chardan’s 9th Annual Genetics Medicines Conference
o October 21, 2025, New York, NY
o Mr. Legros will participate in one-on-one meetings with investors during the conference
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation,ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.
The Company headquarters are in Valencia, Spain.
For more information on ArthemiR™, please visit https://www.arthemir.com or https://clintrials.gov.
For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
Company Contact
Frédéric Legros
Executive Chairman and CEO
flegros@arthexbiotech.com
+33 6 7949 5790
Investor and Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
+1 858-366-3243
